Resonance Health signs UK CRO deal to expand clinical trials services
Resonance Health (ASX:RHT) entered a strategic alliance and master services agreement with UK CRO Image Analysis to include software as a medical device (SaMD) services in global clinical trials, with the initial deal lasting 24 months and targeting high-growth indications such as obesity and metabolic disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.